News for NovoCure Limited (NVCR)

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy to show statistically...

NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ETCompany ParticipantsIngrid Goldberg - IRBill Doyle - Executive...

The headline numbers for NovoCure (NVCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The following slide deck was published by NovoCure Limited in conjunction with their 2025 Q1 earnings call.

Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brac

NovoCure remains a strong buy with robust earnings, growth in cancer treatments, and significant upside potential to Wall Street targets. Read more here.

While the top- and bottom-line numbers for NovoCure (NVCR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

NovoCure Limited (NASDAQ:NVCR) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ETCompany ParticipantsIngrid Goldberg - Investor RelationsBill...

NovoCure (NVCR) delivered earnings and revenue surprises of -79.41% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working t

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights an

NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

We recently compiled a list of the 8 Stocks on Jim Cramer's Radar. In this article, we are going to take a look at where NovoCure Limited (NASDAQ:NVCR) stands against the other stocks on Jim Cramer's...

On CNBC's

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland

Novocure (NVCR) surpasses revenue expectations for 2024, driven by successful launches and increased approval rates.

Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Teva has been a standout, and smaller stocks such as Eco Wave and Beamr have given exceptional returns, but there have also been disappointments.